{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049850","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.072060+00:00","generated_at":"2026-05-16T23:45:45.290222+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"C4 Therapeutics reports Q3 net loss $32.2M, raises $125M; cemsidomide 53% ORR at 100 µg","bullets":["Revenue $11.2M, net loss $32.2M ($0.44 EPS) vs $15.4M revenue and $24.7M loss in Q3 2024.","Completed equity offering of $125M gross proceeds in Oct 2025; potential additional $225M from warrants.","Phase 1 cemsidomide data: 53% ORR at 100 µg dose; one patient achieved MRD-negative complete response.","Entered clinical trial collaboration with Pfizer to evaluate cemsidomide + elranatamab; Pfizer supplies drug at no cost.","Cash $199.8M as of Sep 30, excluding $125M raise; runway extended to end of 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049850","json":"https://secwatch.observer/filing/0001628280-25-049850.json","markdown":"https://secwatch.observer/filing/0001628280-25-049850.md","text":"https://secwatch.observer/filing/0001628280-25-049850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/0001628280-25-049850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/cccc-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:45:45.290222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}